Indomethacin (oral)

Indomethacin (oral)

Clinical data
Pregnancy category	C (Au), C/D (US)
Routes of administration	Oral, rectal, IV, topical
ATC code	C01EB03 (WHO) M01AB01 (WHO), M02AA23 (WHO), S01BC01 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	~100% (oral), 80–90% (rectal)
Protein binding	99%
Metabolism	Hepatic
Elimination half-life	4.5 hours
Excretion	Renal 60%, faecal 33%
Identifiers
IUPAC name 1-(4-chlorobenzoyl)-5-methoxy- 2-methyl-1-H-indole-3-acetic acid
CAS Number	53-86-1
PubChem CID	3715
DrugBank	APRD00109
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H16ClNO4
Molar mass	357.79 g.mol-1

WikiDoc Resources for Indomethacin (oral)
Articles
Most recent articles on Indomethacin (oral) Most cited articles on Indomethacin (oral) Review articles on Indomethacin (oral) Articles on Indomethacin (oral) in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Indomethacin (oral) Images of Indomethacin (oral) Photos of Indomethacin (oral) Podcasts & MP3s on Indomethacin (oral) Videos on Indomethacin (oral)
Evidence Based Medicine
Cochrane Collaboration on Indomethacin (oral) Bandolier on Indomethacin (oral) TRIP on Indomethacin (oral)
Clinical Trials
Ongoing Trials on Indomethacin (oral) at Clinical Trials.gov Trial results on Indomethacin (oral) Clinical Trials on Indomethacin (oral) at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Indomethacin (oral) NICE Guidance on Indomethacin (oral) NHS PRODIGY Guidance FDA on Indomethacin (oral) CDC on Indomethacin (oral)
Books
Books on Indomethacin (oral)
News
Indomethacin (oral) in the news Be alerted to news on Indomethacin (oral) News trends on Indomethacin (oral)
Commentary
Blogs on Indomethacin (oral)
Definitions
Definitions of Indomethacin (oral)
Patient Resources / Community
Patient resources on Indomethacin (oral) Discussion groups on Indomethacin (oral) Patient Handouts on Indomethacin (oral) Directions to Hospitals Treating Indomethacin (oral) Risk calculators and risk factors for Indomethacin (oral)
Healthcare Provider Resources
Symptoms of Indomethacin (oral) Causes & Risk Factors for Indomethacin (oral) Diagnostic studies for Indomethacin (oral) Treatment of Indomethacin (oral)
Continuing Medical Education (CME)
CME Programs on Indomethacin (oral)
International
Indomethacin (oral) en Espanol Indomethacin (oral) en Francais
Business
Indomethacin (oral) in the Marketplace Patents on Indomethacin (oral)
Experimental / Informatics
List of terms related to Indomethacin (oral)

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

For patient information, click here

Indomethacin (INN) or Indomethacin (USAN and former BAN) is a non-steroidal anti-inflammatory drug commonly used to reduce fever, pain, stiffness, and swelling. It works by inhibiting the production of prostaglandins, molecules known to cause these symptoms. It is marketed under many trade names, including Indocin, Indocid, Indochron E-R, and Indocin-SR.

Chemical properties

Indomethacin is a methylated indole derivative and a member of the arylalkanoic acid class of NSAIDs, which includes diclofenac.

Indications

Clinical indications for indomethacin include:

• ankylosing spondylitis
• rheumatoid arthritis
• arthritic gout
• osteoarthritis
• juvenile arthritis
• psoriatic arthritis
• Reiter's syndrome
• Paget's disease of bone
• Bartter syndrome
• pseudogout
• dysmenorrhea (menstrual cramps)
• pericarditis
• bursitis
• tendinitis
• nephrogenic diabetes insipidus (prostaglandin inhibits vasopressin's action in the kidney)
• fever and pain associated with malignant diseases (tumors, bony metastases, lymphogranulomatosis)
• paroxysmal hemicrania, hemicrania continua and migraine
• renal colic (pain due to kidney stones)
• cryoglobulinemia

Indomethacin has also been used clinically to delay premature labor, reduce amniotic fluid in polyhydramnios, and to close patent ductus arteriosus.

Indomethacin is a potent drug with many serious side effects and should not be considered an analgesic for minor aches and pains or fever. The drug is more potent than aspirin, but is not a better analgesic. In mild to moderate pain a standard oral dose of indomethacin proved as effective as 600mg aspirin.

Contraindications

• concurrent peptic ulcer, or history of ulcer disease
• allergy to indomethacin, aspirin, or other NSAIDs
• patients with nasal polyps reacting with an angioedema to other NSAIDs
• children under 2 years of age (with the exception of neonates with patent ductus arteriosus)
• severe pre-existing renal and liver damage
• caution: pre-existing bone marrow damage (frequent blood cell counts are indicated)
• caution: bleeding tendencies of unknown origin (indometacin inhibits platelet aggregation)
• caution: Parkinson's disease, epilepsy, psychotic disorders (indomethacin may worsen these conditions)

Mechanism of action

Main article: Non-steroidal anti-inflammatory drug

Indomethacin is a nonselective inhibitor of cyclooxygenase (COX) 1 and 2, enzymes that participate in prostaglandin synthesis from arachidonic acid. Prostaglandins are hormone-like molecules normally found in the body, where they have a wide variety of effects, some of which lead to pain, fever, and inflammation.

Prostaglandins also cause uterine contractions in pregnant women. Indomethacin is an effective tocolytic agent, able to delay premature labor by reducing uterine contractions through inhibition of PG synthesis in the uterus and possibly through calcium channel blockade.

Indomethacin has two additional modes of actions with clinical importance:

• It inhibits motility of polymorphonuclear leukocytes, similar to colchicine.
• It uncouples oxidative phosphorylation in cartilaginous (and hepatic) mitochondria, like salicylates.

These additional effects account as well for the analgesic and the anti-inflammatory properties.

Indomethacin readily crosses the placenta, and can reduce fetal urine production to treat polyhydramnios. It does so by reducing renal blood flow and increasing renal vascular resistance, possibly by enhancing the effects of vasopressin on the fetal kidneys.

Adverse effects

Since indomethacin inhibits both COX-1 and COX-2, it inhibits the production of prostaglandins in the stomach and intestines which maintain the mucous lining of the gastrointestinal tract. Indometacin, therefore, like other nonselective COX inhibitors, can cause peptic ulcers. The ulcers can result in serious bleeding and/or perforation requiring hospitalization of the patient. Some even die from these complications.

To reduce the possibility of peptic ulcers, indometacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50–200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ranitidine 150 mg at bedtime, or omeprazole 20 mg at bedtime). Other common gastrointestinal complaints, including dyspepsia, heartburn and mild diarrhea are less serious and rarely require discontinuation of indometacin.

Many NSAIDs, but particularly indometacin, cause lithium retention by reducing its excretion by the kidneys. Thus indometacin users have an elevated risk of lithium toxicity. For patients taking lithium (e.g. for treatment of depression or bipolar disorder), less toxic NSAIDs such as sulindac or aspirin, are preferred.

Indometacin also reduces plasma renin activity and aldosterone levels, and increases sodium and potassium retention. It also enhances the effects of vasopressin. Together these may lead to:

• edema (swelling due to fluid retention)
• hyperkalemia (high potassium levels)
• hypernatremia (high sodium levels)
• hypertension (high blood pressure)

The drug may also cause elevations of serum creatinine and more serious renal damage such as acute renal failure, chronic nephritis and nephrotic syndrome. These conditions also often begin with edema and hyperkalema.

Additionally, indometacin quite often causes headache (10 to 20%), sometimes with vertigo and dizziness, hearing loss, tinnitus, blurred vision (with or without retinal damage) and worsens Parkinson's disease, epilepsy, and psychiatric disorders. Cases of life-threatening shock (including angioedema, sweating, severe hypotension and tachycardia as well as acute bronchospasm), severe or lethal hepatitis and severe bone marrow damage have all been reported. Skin reactions and photosensitivity are also possible side effects.

Due to its strong antipyretic activity indometacin may obscure the clinical course of serious infections.

The frequency and severity of side effects and the availability of better tolerated alternatives make indometacin today a drug of second choice. Its use in acute gout attacks and in dysmenorrhea is well-established because in these indications the duration of treatment is limited to a few days only, therefore serious side effects are not likely to occur.

Necessary examinations during longterm treatment

Patients should undergo regular physical examination to detect edema and signs of central nervous side effects. Blood pressure checks will reveal development of hypertension. Periodic serum electrolyte (sodium, potassium, chloride) measurements, complete blood cell counts and assessment of liver enzymes as well as of creatinine (renal function) should be performed. This is particularly important if indometacin is given together with an ACE inhibitor or with potassium-sparing diuretics, because these combinations can lead to hyperkalemia and/or serious kidney failure. No examinations are necessary if only the topical preparations (spray or gel) are applied.

Animal toxicity and human overdose

Indomethacin has a high acute toxicity both for animals (12 mg/kg in rats and 50 mg/kg in mice) and for humans. Exact human data does not exist, but some fatal human cases, particularly in children and adolescents, have been seen.

Generally, overdose in humans causes drowsiness, dizziness, severe headache, mental confusion, paresthesia, numbness of limbs, nausea and vomiting. Severe gastrointestinal bleeding is also possible. Cerebral edema, and cardiac arrest with fatal outcome have been seen in children.

The treatment is symptomatic and largely the same as with diclofenac. However, the possibility of severe GI tract symptoms should be particularly noted.

The risk of overdose after exaggerated local treatment with gel or spray is very limited.

Usual dosage forms

• tablets or capsules 25 and 50mg
• suppositories 50 and 100mg
• modified-release Capsules 75mg
• syrup (25mg/5ml)
• injectable concentrate 50mg for i.m. injection
• spray or gel
• patches containing 0.5% by weight
• 1% topical liquid

History

Indometacin was discovered in 1963 and it was first approved for use in the U.S. by the Food and Drug Administration in 1965. Its mechanism of action, along with several other NSAIDs that inhibit COX, was described in 1971.

References

• Lum G, Aisenbrey G, Dunn M, Berl T, Schrier R, McDonald K (1977). "In vivo effect of indomethacin to potentiate the renal medullary cyclic AMP response to vasopressin" (PDF or scanned copy). J Clin Invest. 59 (1): 8–13. PMID 187624. CS1 maint: Multiple names: authors list (link)
• Akbarpour F, Afrasiabi A, Vaziri N (1985). "Severe hyperkalemia caused by indomethacin and potassium supplementation". South Med J. 78 (6): 756–7. PMID 4002013.CS1 maint: Multiple names: authors list (link)
• Ragheb M (1990). "The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions". J Clin Psychopharmacol. 10 (5): 350–4. PMID 2258452.
• Phelan K, Mosholder A, Lu S (2003). "Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs". J Clin Psychiatry. 64 (11): 1328–34. PMID 14658947. CS1 maint: Multiple names: authors list (link)
• Hart F, Boardman P (1963). "Indomethacin: A new non-steroid anti-inflammatory agent". Br Med J. 5363: 965–70. PMID 14056924.
• Ferreira S, Moncada S, Vane J (1971). "Indomethacin and aspirin abolish prostaglandin release from the spleen". Nat New Biol. 231 (25): 237–9. PMID 5284362. CS1 maint: Multiple names: authors list (link)
• Scherzer P, Wald H, Rubinger D, Popovtzer M (1992). "Indomethacin and sodium retention in the rat: role of inhibition of prostaglandin E2 synthesis". Clin Sci (Lond). 83 (3): 307–11. PMID 1327647. CS1 maint: Multiple names: authors list (link)

External links

• Effects of Perinatal Indomethacin Treatment on Preterm Infants, academic dissertation (PDF)
• Indomethacin, from MedicineNet
• Indomethacin, from Drugs.com
• Indocin: Description, chemistry, ingredients, from RxList.com